Fri, Jul 25, 2014, 8:42 AM EDT - U.S. Markets open in 48 mins.


% | $
Click the to save as a favorite.

Vertex Pharmaceuticals Incorporated Message Board

  • swhitemd50 swhitemd50 Apr 21, 2012 11:00 AM Flag

    GS-7977/ribavirin fails in genotype 1 HCV

    As I expected, The GS-7977/ribavirin regimen has failed in genotype 1 Hepatitis C. The results of the "Electron" study were skewed by a disproportionate number of easy to treat IL28B C/C patients and are not credible. However, the results of their randomized "Quantum" study are credible and show a SVR4 of just 59% in genotype 1 HCV. The SVR12 will be even lower than 59%. Results of the GS-7977/Daclatasvir study in genotype 1 HCV with a 100% SVR4 response and genotype 2/3 with a 91% SVR4 response are truly game changing. But there is no way Gilead will partner with BMY for a phase 3 trial with this treatment regimen because sharing the revenue with BMY will not generate the kind of profits from GS-7977 that would justify the $10.8 billion purchase price of Pharmassett. This is good news for Vertex which will continue making huge profits from Incivek for a longer period of time and it allows more time for Vertex to advance its interferon free HCV treatment regimens through clinical trials.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
95.77-2.37(-2.41%)Jul 24 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.